AMPH (Amphastar Pharmaceuticals) Risk Assessment

View and export this data going back to 2014. Start your Free Trial

What is Amphastar Pharmaceuticals Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Amphastar Pharmaceuticals is: Moderate Risk: Sensitive, better choose undervalued stock.

Competitive Comparison of Amphastar Pharmaceuticals's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amphastar Pharmaceuticals's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Amphastar Pharmaceuticals's Risk Assessment falls into.

Amphastar Pharmaceuticals (NAS:AMPH) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Amphastar Pharmaceuticals Risk Assessment Related Terms

Thank you for viewing the detailed overview of Amphastar Pharmaceuticals's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Amphastar Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amphastar Pharmaceuticals Inc (NAS:AMPH) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

29A:Germany

Address

11570 6th Street, Rancho Cucamonga, CA, USA, 91730

Website

https://www.amphastar.com

Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Executives

Richard K Prins	director
Rong Zhou	officer: EVP, Production	C/O AMPHASTAR PHARMACEUTICALS INC., 11570 SIXTH STREET, RANCHO CUCAMONGA CA 91730
William J Peters	officer: CFO, SVP & Treasurer	C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Yakob Liawatidewi	officer: SVP Corp Admin Center	C/O AMPHASTAR PHARMACEUTICALS INC, 11570 SIXTH STREET, RANCHO CUCAMONGA CA 91730
Floyd F. Petersen	director	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Michael A Zasloff	director
Mary Z. Luo	director, 10 percent owner, officer: COO and Chief Scientist	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Gayle Deflin	director	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Diane G. Gerst	officer: EVP, QA & Regulatory Affairs	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Howard Lee	director	13F-2, NO. 36, LANE 48, SECTION 3, NAN-JING EAST ROAD, TAIPEI, TAIWAN F4 00000
Jack Y. Zhang	director, 10 percent owner, officer: CEO & Chief Scientific Officer	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
David Maris	director	C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Richard Koo	director	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Jason B. Shandell	director, officer: President	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Applied Physics & Chemistry Laboratories, Inc.	10 percent owner	13760 MAGNOLIA AVENUE, CHINO CA 91710